vs
ASP Isotopes Inc.（ASPI）与Journey Medical Corp（DERM）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Journey Medical Corp的1.0倍（$16.7M vs $16.1M），ASP Isotopes Inc.同比增速更快（1295.7% vs 27.3%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
ASPI vs DERM — 直观对比
营收规模更大
ASPI
是对方的1.0倍
$16.1M
营收增速更快
ASPI
高出1268.4%
27.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $16.1M |
| 净利润 | — | $-1.2M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -2.8% |
| 净利率 | — | -7.8% |
| 营收同比 | 1295.7% | 27.3% |
| 净利润同比 | -586.8% | -182.0% |
| 每股收益（稀释后） | — | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIDERM
| Q4 25 | $16.7M | $16.1M | ||
| Q3 25 | $4.9M | $17.0M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $14.9M | ||
| Q1 24 | — | $13.0M |
净利润ASPIDERM
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $-12.9M | $-2.3M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-10.4M |
毛利率ASPIDERM
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
营业利润率ASPIDERM
| Q4 25 | — | -2.8% | ||
| Q3 25 | -306.1% | -9.0% | ||
| Q2 25 | — | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | -19.8% | ||
| Q2 24 | — | -19.7% | ||
| Q1 24 | — | -77.4% |
净利率ASPIDERM
| Q4 25 | — | -7.8% | ||
| Q3 25 | -263.7% | -13.6% | ||
| Q2 25 | — | -25.3% | ||
| Q1 25 | — | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | — | -22.6% | ||
| Q1 24 | — | -80.1% |
每股收益（稀释后）ASPIDERM
| Q4 25 | — | $-0.04 | ||
| Q3 25 | $-0.15 | $-0.09 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | — | $-0.17 | ||
| Q1 24 | — | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $24.1M |
| 总债务越低越好 | $14.4M | $25.3M |
| 股东权益账面价值 | $204.2M | $31.9M |
| 总资产 | $498.0M | $94.6M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.79× |
8季度趋势，按日历期对齐
现金及短期投资ASPIDERM
| Q4 25 | $333.3M | $24.1M | ||
| Q3 25 | $113.9M | $24.9M | ||
| Q2 25 | — | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | — | $23.9M | ||
| Q1 24 | — | $24.1M |
总债务ASPIDERM
| Q4 25 | $14.4M | $25.3M | ||
| Q3 25 | $13.9M | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
股东权益ASPIDERM
| Q4 25 | $204.2M | $31.9M | ||
| Q3 25 | $74.1M | $25.9M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $11.3M | ||
| Q1 24 | — | $13.0M |
总资产ASPIDERM
| Q4 25 | $498.0M | $94.6M | ||
| Q3 25 | $225.9M | $85.2M | ||
| Q2 25 | — | $81.2M | ||
| Q1 25 | — | $85.0M | ||
| Q4 24 | — | $80.2M | ||
| Q3 24 | — | $64.0M | ||
| Q2 24 | — | $65.2M | ||
| Q1 24 | — | $66.6M |
负债/权益比ASPIDERM
| Q4 25 | 0.07× | 0.79× | ||
| Q3 25 | 0.19× | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-6.3M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIDERM
| Q4 25 | $-37.8M | $-6.3M | ||
| Q3 25 | $-8.9M | $-2.4M | ||
| Q2 25 | — | $-942.0K | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-5.2M | ||
| Q1 24 | — | $-5.0M |
自由现金流ASPIDERM
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASPIDERM
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASPIDERM
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ASPIDERM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
